Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethanol | 28 | 2019 | 195 | 4.520 |
Why?
|
| Social Isolation | 12 | 2018 | 41 | 3.290 |
Why?
|
| Synaptic Transmission | 20 | 2018 | 124 | 2.790 |
Why?
|
| Alcohol Drinking | 9 | 2018 | 255 | 2.500 |
Why?
|
| Synapses | 15 | 2018 | 87 | 2.410 |
Why?
|
| Anxiety | 9 | 2019 | 190 | 2.290 |
Why?
|
| Amygdala | 10 | 2013 | 60 | 2.220 |
Why?
|
| Central Nervous System Depressants | 9 | 2018 | 63 | 2.020 |
Why?
|
| Hippocampus | 25 | 2019 | 216 | 1.920 |
Why?
|
| Pyramidal Cells | 8 | 2015 | 18 | 1.840 |
Why?
|
| Rats | 47 | 2018 | 1895 | 1.690 |
Why?
|
| Rats, Long-Evans | 20 | 2018 | 92 | 1.540 |
Why?
|
| Animals | 64 | 2019 | 8199 | 1.490 |
Why?
|
| gamma-Aminobutyric Acid | 11 | 2012 | 82 | 1.470 |
Why?
|
| Fear | 3 | 2016 | 42 | 1.390 |
Why?
|
| Nucleus Accumbens | 8 | 2018 | 121 | 1.310 |
Why?
|
| Alcoholism | 3 | 2017 | 97 | 1.220 |
Why?
|
| Receptors, GABA-A | 14 | 2012 | 32 | 1.120 |
Why?
|
| Excitatory Postsynaptic Potentials | 9 | 2015 | 33 | 1.070 |
Why?
|
| Norepinephrine | 7 | 2020 | 101 | 1.070 |
Why?
|
| Extinction, Psychological | 3 | 2015 | 17 | 1.020 |
Why?
|
| Neurons | 17 | 2020 | 486 | 0.980 |
Why?
|
| Adenosine | 3 | 2015 | 68 | 0.940 |
Why?
|
| Stress, Psychological | 4 | 2018 | 217 | 0.910 |
Why?
|
| Receptors, Kainic Acid | 6 | 2008 | 8 | 0.890 |
Why?
|
| Male | 50 | 2019 | 19441 | 0.820 |
Why?
|
| Inhibitory Postsynaptic Potentials | 4 | 2016 | 8 | 0.750 |
Why?
|
| Disease Models, Animal | 10 | 2018 | 1083 | 0.720 |
Why?
|
| Rats, Sprague-Dawley | 20 | 2013 | 897 | 0.720 |
Why?
|
| Dopamine | 7 | 2018 | 262 | 0.690 |
Why?
|
| Alcohol-Related Disorders | 2 | 2018 | 21 | 0.680 |
Why?
|
| Interneurons | 7 | 2019 | 24 | 0.670 |
Why?
|
| Receptors, GABA-B | 5 | 2009 | 19 | 0.670 |
Why?
|
| Ethanolamines | 3 | 2015 | 10 | 0.600 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 4 | 2018 | 35 | 0.580 |
Why?
|
| Patch-Clamp Techniques | 14 | 2015 | 76 | 0.570 |
Why?
|
| Prazosin | 2 | 2015 | 11 | 0.540 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 61 | 0.530 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2017 | 39 | 0.520 |
Why?
|
| Autoreceptors | 2 | 2009 | 9 | 0.510 |
Why?
|
| Behavior, Animal | 4 | 2014 | 299 | 0.510 |
Why?
|
| Alcohol-Induced Disorders, Nervous System | 1 | 2016 | 8 | 0.500 |
Why?
|
| Anti-Anxiety Agents | 3 | 2015 | 12 | 0.490 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 42 | 0.480 |
Why?
|
| Self Administration | 7 | 2018 | 382 | 0.480 |
Why?
|
| Housing, Animal | 2 | 2014 | 23 | 0.480 |
Why?
|
| Locomotion | 2 | 2013 | 34 | 0.460 |
Why?
|
| Conditioning, Classical | 1 | 2015 | 30 | 0.460 |
Why?
|
| Anxiety Disorders | 1 | 2016 | 71 | 0.460 |
Why?
|
| Age Factors | 8 | 2019 | 1179 | 0.450 |
Why?
|
| Synaptic Membranes | 1 | 2015 | 3 | 0.450 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2015 | 7 | 0.450 |
Why?
|
| Methylphenidate | 2 | 2015 | 36 | 0.450 |
Why?
|
| Action Potentials | 2 | 2015 | 212 | 0.430 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2014 | 5 | 0.420 |
Why?
|
| Thiophenes | 1 | 2014 | 24 | 0.410 |
Why?
|
| Electric Stimulation | 9 | 2016 | 135 | 0.410 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2013 | 9 | 0.410 |
Why?
|
| Alcoholic Intoxication | 1 | 2013 | 28 | 0.380 |
Why?
|
| GABA Modulators | 4 | 2009 | 9 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2015 | 717 | 0.370 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2012 | 8 | 0.370 |
Why?
|
| Neural Inhibition | 4 | 2006 | 33 | 0.360 |
Why?
|
| Insulin-Like Growth Factor I | 4 | 2012 | 85 | 0.340 |
Why?
|
| Receptors, Adrenergic, beta-3 | 1 | 2010 | 12 | 0.320 |
Why?
|
| Locus Coeruleus | 2 | 2020 | 23 | 0.300 |
Why?
|
| Brain | 2 | 2016 | 965 | 0.300 |
Why?
|
| Microinjections | 3 | 2015 | 39 | 0.290 |
Why?
|
| Neuronal Plasticity | 3 | 2017 | 84 | 0.280 |
Why?
|
| Motor Activity | 3 | 2008 | 332 | 0.270 |
Why?
|
| Bicuculline | 5 | 2013 | 10 | 0.270 |
Why?
|
| Analysis of Variance | 6 | 2015 | 471 | 0.260 |
Why?
|
| Animals, Newborn | 5 | 2015 | 136 | 0.260 |
Why?
|
| Protein-Serine-Threonine Kinases | 2 | 2018 | 49 | 0.250 |
Why?
|
| Random Allocation | 4 | 2015 | 247 | 0.250 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2016 | 8 | 0.240 |
Why?
|
| Excitatory Amino Acid Agonists | 5 | 2011 | 17 | 0.240 |
Why?
|
| Protein Kinase C | 3 | 1997 | 43 | 0.240 |
Why?
|
| Corpus Striatum | 2 | 2015 | 69 | 0.220 |
Why?
|
| Choice Behavior | 3 | 2016 | 84 | 0.220 |
Why?
|
| Aging | 4 | 2015 | 942 | 0.220 |
Why?
|
| Long-Term Potentiation | 2 | 2017 | 14 | 0.220 |
Why?
|
| Receptors, GABA | 2 | 1994 | 7 | 0.220 |
Why?
|
| Drug Interactions | 4 | 2010 | 86 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Morpholines | 4 | 2010 | 47 | 0.210 |
Why?
|
| Central Nervous System Stimulants | 2 | 2015 | 82 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.210 |
Why?
|
| Dentate Gyrus | 1 | 2003 | 5 | 0.200 |
Why?
|
| GABA Antagonists | 4 | 2010 | 14 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2011 | 7 | 0.200 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2015 | 31 | 0.200 |
Why?
|
| Propranolol | 2 | 2015 | 17 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2015 | 90 | 0.190 |
Why?
|
| Presynaptic Terminals | 2 | 2018 | 39 | 0.180 |
Why?
|
| Excitatory Amino Acid Antagonists | 4 | 2011 | 28 | 0.180 |
Why?
|
| Electrophysiology | 10 | 2006 | 76 | 0.170 |
Why?
|
| Prefrontal Cortex | 2 | 2019 | 85 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Conditioning, Operant | 2 | 2013 | 122 | 0.160 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 1997 | 16 | 0.160 |
Why?
|
| Kainic Acid | 3 | 2006 | 11 | 0.160 |
Why?
|
| Demyelinating Diseases | 1 | 2019 | 9 | 0.150 |
Why?
|
| Humans | 10 | 2017 | 32282 | 0.150 |
Why?
|
| Growth Hormone | 2 | 2012 | 15 | 0.150 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Gene Expression | 2 | 2018 | 346 | 0.140 |
Why?
|
| Mice | 6 | 2019 | 2571 | 0.140 |
Why?
|
| Colchicine | 1 | 1998 | 8 | 0.140 |
Why?
|
| Evoked Potentials | 4 | 2018 | 17 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 37 | 0.130 |
Why?
|
| Nervous System | 1 | 1997 | 12 | 0.130 |
Why?
|
| Baclofen | 2 | 2009 | 26 | 0.130 |
Why?
|
| Imidazoles | 1 | 2016 | 97 | 0.120 |
Why?
|
| Biophysics | 2 | 2013 | 13 | 0.120 |
Why?
|
| Ventral Tegmental Area | 1 | 2016 | 35 | 0.120 |
Why?
|
| Reward | 1 | 2016 | 64 | 0.120 |
Why?
|
| Synaptic Potentials | 1 | 2015 | 5 | 0.120 |
Why?
|
| Motor Cortex | 1 | 2015 | 13 | 0.120 |
Why?
|
| Calcium Channel Agonists | 1 | 2015 | 1 | 0.120 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 5 | 0.110 |
Why?
|
| Electrochemical Techniques | 1 | 2015 | 26 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2015 | 31 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2016 | 154 | 0.110 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 20 | 0.110 |
Why?
|
| Guanine Nucleotides | 1 | 1994 | 1 | 0.110 |
Why?
|
| Enzyme Inhibitors | 5 | 2005 | 174 | 0.110 |
Why?
|
| Female | 6 | 2017 | 19945 | 0.110 |
Why?
|
| Research | 1 | 2015 | 81 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 565 | 0.110 |
Why?
|
| Calcium | 5 | 2006 | 339 | 0.110 |
Why?
|
| Maze Learning | 3 | 2019 | 15 | 0.110 |
Why?
|
| Sucrose | 1 | 2013 | 19 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2014 | 173 | 0.100 |
Why?
|
| Motivation | 1 | 2013 | 120 | 0.090 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 3 | 1997 | 4 | 0.090 |
Why?
|
| Electrophysiological Phenomena | 1 | 2012 | 29 | 0.090 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2012 | 43 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2011 | 100 | 0.080 |
Why?
|
| Time Factors | 2 | 2015 | 2205 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 478 | 0.080 |
Why?
|
| Pentobarbital | 2 | 2004 | 4 | 0.080 |
Why?
|
| Thionucleotides | 1 | 2010 | 5 | 0.080 |
Why?
|
| Exploratory Behavior | 1 | 2010 | 33 | 0.080 |
Why?
|
| Cyclic AMP | 1 | 2010 | 55 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 59 | 0.080 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2009 | 5 | 0.080 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2009 | 12 | 0.080 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 3 | 2015 | 112 | 0.080 |
Why?
|
| Receptors, Glycine | 2 | 2000 | 8 | 0.080 |
Why?
|
| Rats, Wistar | 5 | 1997 | 111 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2007 | 66 | 0.070 |
Why?
|
| Extracellular Space | 3 | 2015 | 28 | 0.070 |
Why?
|
| Receptors, Adrenergic | 1 | 2007 | 13 | 0.070 |
Why?
|
| Species Specificity | 2 | 2006 | 98 | 0.060 |
Why?
|
| Receptors, AMPA | 2 | 2011 | 16 | 0.060 |
Why?
|
| Androstadienes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Genistein | 1 | 2005 | 17 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 792 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2018 | 413 | 0.060 |
Why?
|
| Flunitrazepam | 1 | 2004 | 3 | 0.060 |
Why?
|
| Spatial Behavior | 1 | 2004 | 11 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2016 | 854 | 0.050 |
Why?
|
| Receptors, Drug | 1 | 2003 | 19 | 0.050 |
Why?
|
| Lidocaine | 1 | 2003 | 19 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 1998 | 264 | 0.050 |
Why?
|
| Cannabinoids | 1 | 2003 | 56 | 0.050 |
Why?
|
| Receptors, Purinergic P1 | 1 | 2002 | 11 | 0.050 |
Why?
|
| Membrane Potentials | 3 | 1997 | 76 | 0.050 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2002 | 23 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1300 | 0.050 |
Why?
|
| Glutamic Acid | 1 | 2002 | 50 | 0.040 |
Why?
|
| Rats, Inbred F344 | 2 | 2012 | 151 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 542 | 0.040 |
Why?
|
| Drinking Behavior | 1 | 2020 | 11 | 0.040 |
Why?
|
| Intracellular Membranes | 2 | 1997 | 9 | 0.040 |
Why?
|
| N-Methylaspartate | 1 | 1999 | 13 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2013 | 727 | 0.040 |
Why?
|
| Bungarotoxins | 1 | 1998 | 2 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 1998 | 839 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1998 | 43 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 1998 | 61 | 0.030 |
Why?
|
| Binding Sites | 1 | 1998 | 144 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 1997 | 43 | 0.030 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 1997 | 6 | 0.030 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2018 | 147 | 0.030 |
Why?
|
| Dendrites | 1 | 1997 | 17 | 0.030 |
Why?
|
| Drug Resistance | 1 | 1997 | 42 | 0.030 |
Why?
|
| Cold Temperature | 1 | 1997 | 56 | 0.030 |
Why?
|
| Adenosine Triphosphate | 2 | 1994 | 71 | 0.030 |
Why?
|
| Epilepsy | 1 | 1997 | 79 | 0.030 |
Why?
|
| Consummatory Behavior | 1 | 2016 | 4 | 0.030 |
Why?
|
| Periodicity | 1 | 2016 | 11 | 0.030 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 10 | 0.030 |
Why?
|
| Ion Channel Gating | 1 | 1995 | 20 | 0.030 |
Why?
|
| Tail | 1 | 2015 | 5 | 0.030 |
Why?
|
| Carbon | 1 | 2015 | 13 | 0.030 |
Why?
|
| Time | 1 | 2015 | 27 | 0.030 |
Why?
|
| Dopamine Agents | 1 | 2015 | 21 | 0.030 |
Why?
|
| Norepinephrine Plasma Membrane Transport Proteins | 1 | 2015 | 10 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 83 | 0.030 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 54 | 0.030 |
Why?
|
| Amphetamine | 1 | 2015 | 43 | 0.030 |
Why?
|
| Microdialysis | 1 | 2015 | 41 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 83 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 1994 | 10 | 0.030 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1994 | 35 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 299 | 0.030 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 1994 | 2 | 0.030 |
Why?
|
| Diazepam | 1 | 1993 | 5 | 0.030 |
Why?
|
| Adult | 1 | 2016 | 9259 | 0.020 |
Why?
|
| Pain | 1 | 2015 | 304 | 0.020 |
Why?
|
| Exocytosis | 1 | 2013 | 11 | 0.020 |
Why?
|
| Aged | 1 | 2016 | 10263 | 0.020 |
Why?
|
| Muscarine | 1 | 1992 | 1 | 0.020 |
Why?
|
| Rats, Inbred BN | 1 | 2012 | 31 | 0.020 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2013 | 80 | 0.020 |
Why?
|
| Middle Aged | 1 | 2016 | 11851 | 0.020 |
Why?
|
| Cocaine | 1 | 2015 | 354 | 0.020 |
Why?
|
| Glycine | 1 | 2011 | 26 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 150 | 0.020 |
Why?
|
| Marine Toxins | 2 | 2003 | 4 | 0.020 |
Why?
|
| Oxazoles | 2 | 2003 | 7 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2012 | 349 | 0.020 |
Why?
|
| Oocytes | 2 | 2000 | 45 | 0.020 |
Why?
|
| Ion Channels | 2 | 1998 | 26 | 0.020 |
Why?
|
| Saccharin | 1 | 2006 | 2 | 0.020 |
Why?
|
| Quinine | 1 | 2006 | 4 | 0.020 |
Why?
|
| Etomidate | 1 | 2006 | 5 | 0.020 |
Why?
|
| Body Temperature | 1 | 2006 | 20 | 0.020 |
Why?
|
| Reflex | 1 | 2006 | 20 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 87 | 0.020 |
Why?
|
| Xenopus | 2 | 1996 | 4 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2006 | 42 | 0.020 |
Why?
|
| Cell Size | 1 | 2006 | 40 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2006 | 46 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 246 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 94 | 0.010 |
Why?
|
| Phosphorylation | 2 | 1998 | 250 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 622 | 0.010 |
Why?
|
| Glutamate Decarboxylase | 1 | 2004 | 17 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 25 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 54 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2004 | 44 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 67 | 0.010 |
Why?
|
| omega-Conotoxin GVIA | 1 | 2003 | 7 | 0.010 |
Why?
|
| Sodium Channel Blockers | 1 | 2003 | 7 | 0.010 |
Why?
|
| Enzyme Activators | 1 | 2003 | 8 | 0.010 |
Why?
|
| Benzoxazines | 1 | 2003 | 28 | 0.010 |
Why?
|
| Receptors, Cannabinoid | 1 | 2003 | 33 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2003 | 53 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2003 | 53 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 2000 | 4 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2000 | 43 | 0.010 |
Why?
|
| Anesthetics, Inhalation | 1 | 2000 | 17 | 0.010 |
Why?
|
| Aconitine | 1 | 1998 | 5 | 0.010 |
Why?
|
| Nicotinic Antagonists | 1 | 1998 | 17 | 0.010 |
Why?
|
| Insecticides | 1 | 1998 | 15 | 0.010 |
Why?
|
| Nicotinic Agonists | 1 | 1998 | 39 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1997 | 18 | 0.010 |
Why?
|
| Temperature | 1 | 1997 | 58 | 0.010 |
Why?
|
| Cell Line | 1 | 1998 | 454 | 0.010 |
Why?
|
| Phalloidine | 1 | 1996 | 1 | 0.010 |
Why?
|
| Receptors, Glutamate | 1 | 1996 | 6 | 0.010 |
Why?
|
| Nicotine | 1 | 1998 | 164 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1995 | 18 | 0.010 |
Why?
|
| src Homology Domains | 1 | 1995 | 16 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1995 | 12 | 0.010 |
Why?
|
| Kinetics | 1 | 1996 | 250 | 0.010 |
Why?
|
| Sulfuric Acid Esters | 1 | 1994 | 1 | 0.010 |
Why?
|
| Anions | 1 | 1994 | 3 | 0.010 |
Why?
|
| Gluconates | 1 | 1994 | 4 | 0.010 |
Why?
|
| Citrates | 1 | 1994 | 5 | 0.010 |
Why?
|
| Chlorides | 1 | 1994 | 13 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1994 | 20 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 408 | 0.010 |
Why?
|
| Flumazenil | 1 | 1993 | 1 | 0.010 |
Why?
|
| Potassium Channels | 1 | 1993 | 20 | 0.010 |
Why?
|
| Potassium | 1 | 1992 | 40 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1992 | 40 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1992 | 138 | 0.010 |
Why?
|
| Homeostasis | 1 | 1993 | 130 | 0.010 |
Why?
|